PURPOSE OF REVIEW: Cell therapies for inherited @entity121 are based on the implantation of normal or genetically corrected myogenic cells into the body. This review summarizes the recent progress in this field, systematized according to the factors important for success. RECENT FINDINGS: In the choice of donor cells, myoblasts derived from satellite cells remain the best choice. Some studies on the population of muscle-derived stem cells in @entity19 suggested that these cells may have some advantages over myoblasts; however, no results supporting this advantage have been presented in a primate model. Recent studies on bone marrow transplantation as a systemic source of myogenic precursors for the treatment of @entity121 were disappointing. Concerning donor cell delivery, intramuscular myoblast injection remains the only way that can significantly introduce exogenous myogenic cells into the muscles. A recent study in primates showed some parameters of myoblast injection that could be useful in the @entity1 . Progress was made in @entity19 to understand the factors that could favor the migration of the donor myoblasts in the host muscles. Concerning donor cell survival, analysis of immune cell infiltration dynamics allowed a better understanding of the factors implicated in early donor cell death. Progress was made on the control of acute rejection for myoblast transplantation in primates. So far, few @entity19 experiments have advanced the field of tolerance induction toward myogenic cells. SUMMARY: Myoblast transplantation (intramuscular injection of satellite cell-derived myoblasts) currently remains the only cell-based therapy that has produced promising results in the context of a preclinical model such as the nonhuman primate.

Cell therapies for inherited XXXX .

@entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity1 :: ('9606', 'Species') :: ['human'] @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathies']
@entity121 :: (MESH:D009135,Disease) :: ['myopathies']
